In a phase 3 trial, toripalimab-based chemotherapy with radiotherapy without concurrent cisplatin achieved noninferior 3-year failure-free survival compared with standard therapy in patients with ...

SHANGHAI, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...

New findings from a study conducted by the Indian Institute of Science (IISc) claims to have important therapeutic implications in the treatment of diabetes. An IISc release said just as smart traffic ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery ...

Weight-Loss Pill Matches Injections, but Experts Skeptical Participants on the 36 mg oral dose drop 12.4% of their body weight at 72 weeks, yet physicians warn of posttreatment weight rebound.